• 9 November 2006
  • News
  • By

BioSuppliers News


Bio-Rad, ICT to promote cost effective solutions

Bio-Rad Laboratories India (Bio-Rad India) has joined hands with the Institute of Chemical Technology (ICT), Mumbai to promote cost effective solutions for the Indian biotechnology and biopharma industry. As part of this initiative, Bio-Rad India organized a seminar on "Challenges and Solutions in Modern Chromatographic Separations" which was attended by eminent scientists and biotechnologists.

Speaking at the seminar, Prof. Arvind Lali of the Institute of Chemical Technology said, "A facility has been set up at ICT to provide 'separation solutions', both in part and full, to the rapidly growing Indian biotech and pharma industries. Technical expertise at ICT combined with the wide product support from Bio-Rad India is expected to provide the 'missing link' between bench scale technologies and successful commercial ventures through cost effective separation solutions using modern equipment
and technology."

"The broad objective of the initiative is to develop and enhance the science of chromatographic separation and generate manpower and expertise for Indian biotechnology and pharma industries. It is also aimed at providing an equipped laboratory facility where developmental work can be carried out to assist the industry in their separation problems," said Himanshu, division manager, life sciences, Bio-Rad India.

Chromatography is used as a vital tool at various stages from R&D to production in labs or organizations, which are involved in research and development, quality assurance and controls and manufacturing (production). It is one of the most trusted and established techniques in new drug discovery, vaccine manufacturing and development, generic drugs production and research. Bio-Rad offers a wide range of resins, media, lab scale systems and production scale systems.


Praj posts 150% rise in profits in H1

Praj Industry, a Pune-based global ethanol and brewery technology major, has registered over150 percent growth in the profit for the first half of current financial year 2006-07. The company's PBT for H1 stood at Rs 33.59 crore (against the corresponding period of last year's PBT at Rs 13.48 crore) and similarly the PAT at Rs. 25.89 crore (Rs 10.26 crore). Even the total income generated during the H1 was higher by 158 percent to Rs 148.76 crore (Rs 57.68 crore).

Pramod Chaudhari, chairman, Praj Industries, said, "We are seeing a major acceleration in the performance as envisaged. The half-year turnover is almost equivalent to last whole year's level. Going by the orders on hand and in the pipeline, we shall aim to exceed annual targeted sales of $100 million (Rs 450 crore). And the pending orders, as at end September 2006 are in the region of Rs 600 crore."

The consolidation efforts undertaken by the company in the previous years are bearing fruit this year. The addition of two manufacturing shops equipped with automated machinery, and increased manpower base has enabled Praj to upscale its production levels. The results are already visible in this half year, wherein the company has doubled its turnover on the back of a strong base. Praj continues to add to its resources.

Pramod Chaudhari announced finalization of plans to set up yet another manufacturing shop in Kandla SEZ, which will further augment the capacity, especially for export orders. This shop is expected to roll out equipment by the end of this fiscal.


Eppendorf develops Biochip to test non-approved GMO in food

Eppendorf Biochip Systems GmbH, a global supplier of biotechnology systems and research tools, has developed an innovative detection method for genetically modified organisms (GMOs), which both detects GMOs currently approved by the EU and reliably tests for the presence of non-approved GMOs.
The technical principle is based on the detection of specific DNA elements used only in GMO plants. The Eppendorf method combines the information obtained from the test under software guidance to come to a conclusion on genetically engineered organisms. The advantage compared to conventional tests is that it can detect numerous individual elements of one gene library simultaneously. These specific patterns are located on a biochip, visualized, and evaluated by means of matching software.

"Frequently, time-consuming laboratory tests are the only means of differentiating food contamination. The laboratories must know which genetic modifications they are looking for in the bulk of hereditary substance. The non-approved LL601 variety can be detected with our test procedure. Our test is already capable of detecting about 60 percent of all GMOs known in literature," said Dr Sven Bülow, managing director of Eppendorf Biochip Systems.


Dionex acquires media technology from Teledyne

Dionex Corporation, a manufacturer and marketer of chromatography systems for chemical analysis, has announced the acquisition of the SWIFT monolithic liquid chromatography media products, intellectual property, technology and other related assets from Teledyne Isco (a subsidiary of Teledyne Technologies) in an all-cash transaction.

This deal expands and strengthens Dionex' leading polymer bead-based separation media technology platform for ion chromatography and HPLC, and enables the company to enter new liquid chromatography applications in nano, capillary, analytical and preparative flow formats.

In addition to this, Dionex Corporation has recently agreed to exchange control codes for their chromatography instrumentation with Agilent Technologies. The agreement provides Dionex with control codes for the Agilent 1100 and 1200 liquid chromatographs (including the 1200 Rapid Resolution LC and the single quadrupole MSDs) and provides Agilent with control codes for the majority of the Dionex liquid chromatographs (HPLC and IC).


LabVantage Solutions opens branch office in Mumbai

LabVantage Solutions, a provider of enterprise solutions tailored for laboratories, has set up a branch office in Mumbai to serve the customers of south India and also the upcoming Middle East countries.

Anil Kastuar, president-Asia Pacific, LabVantage Solutions, said, "Initially we will have about 10 personnel working from this new location in sales, implementation consulting and service support areas. We are planning to increase the headcount to 25–30 in the next 12 months as the business grows. This will help to serve the customers in a better way and also offer support services at the customers given time."

He further noted that LabVantage sees a lot of potential for its range of LIMS as the pharma and biotechnology industries, which are mainly based in south and western region of India and are growing.

Recently LabVantage tied up with SAP to offer SAP NetWeaver platform to its customers. It has also expanded its software and testing R&D center at Kolkata. At present, LabVantage Solutions India has a total strength of about 110 and has registered a 100 percent growth against the last year.


PerkinElmer partners with Ion Signature Technology

PerkinElmer has announced a new partnership with Ion Signature Technology (IST). With this partnership, the users of the new PerkinElmer Clarus 600 GC/MS now have the option to incorporate Ion Signature Quantitative Deconvolution Software customized for the Clarus family during data processing for fast and accurate data review and evaluation.

The recently launched family of Clarus 600 GC/MS systems delivers high performance and increased sample throughput. For many laboratories, adding the Ion Signature option further enhances the Clarus system's ability to deliver faster results on unknowns.

The Ion Signature FileConvert software package, designed specifically for use with the PerkinElmer Clarus GC/MS series, is a key deconvolution tool in the marketplace. It addresses the needs of the full spectrum of GC/MS users, including environmental contract, forensics, food and beverage, flavor and fragrance, petrochemical and chemical quality-control (QC) laboratories. In these market segments, users face unique co-eluting challenges when multiple components or contaminants overlap at the results stage, which make the clear interpretation of data difficult.


Thermo and Fisher Scientific receive early termination from FTC

Thermo Electron Corporation and Fisher Scientific International have announced that the US Federal Trade Commission (FTC) has approved a consent order requiring the divestiture of Fisher's Genevac business – a $17 million product line – and granted the companies early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the pending merger of Thermo and Fisher. No further regulatory review is necessary in the US for the parties to close the merger.

The companies also announced that, following discussions with the European Commission regarding their proposed merger, they have offered to divest the same Genevac business. As a result, the initial deadline for the European Commission to rule on the merger has been extended to November 9, 2006. Thermo and Fisher anticipate that this proposal will resolve any issues raised by the European Commission regarding the merger. Assuming the European Commission clears the transaction on November 9, 2006, the parties intend to complete the merger on that date.

It may be recalled that on August 30, both Thermo Electron Corporation and Fisher Scientific International had announced that the stockholders of both companies have voted to approve their merger. At the Fisher stockholders meeting, more than 99 percent of the shares represented were voted in favor of the transaction, constituting a significant majority of the outstanding Fisher shares. More than 98 percent of the Thermo shares represented at the Thermo meeting were voted in favor of the issuance of shares in the transaction. In addition, more than 94 percent of the Thermo shares voted, representing a significant majority of the outstanding shares, approved the amendment of Thermo's certificate of incorporation to increase the number of shares of Thermo's common stock to 1.2 billion and to change the company's name upon the completion of the merger to Thermo Fisher Scientific.


PerkinElmer's bio-imaging products

PerkinElmer has introduced three new bio-imaging products to enable earlier detection of disease indicators and faster discovery of effective new drugs. The new imaging products are:

The Geliance family of gel imaging products for DNA, RNA and proteins – Gel imaging is a new offering in PerkinElmer's bio-imaging family, and provides proteomic and genomic researchers with a system to help manage increasingly heavy workloads and meet ever-compressed deadlines. The Geliance family offers top-of-the- line optical performance, easy-to-use hardware, and software to customers looking for fluorescence and chemiluminescence imaging solutions.

The PhotoKinesis Accessory for the UltraVIEW Live Cell Imaging System –The accessory was designed to enable Fluorescence Recovery After Photobleaching (FRAP) and similar techniques to be performed on PerkinElmer's UltraVIEW system. Researchers can now improve their ability to study fast-moving cells and rapid events in live cells, with point-and-click ease. The new "Track-It" technology offers real- time photoactivation and photoswitching for greater control over experiments and greater biologically relevant data from samples.

The Spotlight 400 FT-IR Imaging System – The system is designed to enable labs to run more samples per day and provides greater understanding of materials with faster data collection, more sampling and longer unattended operating time. Spotlight imaging systems are now utilized in biomedical imaging research to detect disease indicators at earlier stages, given their excellent image quality and high-throughput performance for tissue analysis.


Whatman Protein Biochip receives CE Registration

Whatman, a global leader in separations and protein array technology, announced that its multiplex protein biochip, branded CombiChip, has received CE Registration for the detection of autoimmune diseases. This assay system was developed in a partnership with Privates Institut für Immunologie und Molekulargenetik GmbH (IIM), a German laboratory that specializes in autoimmune and other clinical diagnostic assays. Whatman plans to make the CombiChip available to reference laboratories as a CE-marked in-vitro diagnostic kit.

The biochip, which only requires a single, low volume serum sample to generate results for 14 different analytes, effectively reduces the time of analysis to two or three hours.

"Conventional methods of autoimmune diagnosis rely on single ELISAs, Immunoblots or Farr/Crithidia assays for each different analyte. However, this protein biochip for autoimmune detection will be a major step forward for our lab and others, because the ability to generate multiple results from a single sample significantly reduces the time, effort and cost of autoimmune analysis," said Dr Appelhans, general manager at IIM.


Corning, Thermo, FIBERLite collaborate for sample processing solution

Corning Incorporated, in conjunction with Thermo Electron Corporation and FIBERLite, have announced an innovative sample processing solution that cuts laboratory research processing time in half. The solution seamlessly brings together Thermo's Sorvall RC-6 Plus super-speed centrifuge and FIBERLite's high-performance carbon fiber rotors with Corning's high-quality disposable centrifuge tubes to create a total sample processing solution. Combined, the three products allow scientists to produce more reliable results faster by enabling researchers to do multiple separations with just one tube. This is the first product combination of its kind and it is expected to revolutionize the way researchers do preparation work.

"Our customers are increasingly demanding disposable product solutions that minimize the risk of contamination, thus making their research more accurate. Particularly with sample processing, many customers have been reusing pricey non-disposable tubes and attempting to sterilize them on their own," said Steve Wood, division vice president, commercial operations, Corning Life Sciences.

Billy McKnight, vice president and general manager, sample preparation and separation, Thermo Electron Corporation, said, "Our customers are constantly seeking solutions that help them accelerate their research efforts. By offering them this unique combined solution comprising best-of-breed products, we are helping them achieve this goal."

"We are pleased to work with two other industry innovators to deliver a revolutionary technology to the market that lowers the total process cost and directly responds to the needs of customers," said Al Piramoon, president and CEO, FIBERLite.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email